

Published in final edited form as:


Org Lett. 2009 April 16; 11(8): 1849–1851. doi:10.1021/ol900360h.

Asymmetric Total Synthesis of the Iridoid β -Glucoside (+)-Geniposide *via* Phosphine Organocatalysis

Regan A. Jones and Michael J. Krische*

University of Texas at Austin, Department of Chemistry and Biochemistry, Austin, TX 78712. USA

Abstract



Phosphine catalyzed [3+2] cycloaddition of ethyl-2,3-butadienoate with enone (*S*)-3b occurs with high levels of regio- and stereocontrol to deliver the *cis*-fused cyclopenta[*c*]pyran 4 characteristic of the iridoid family of natural products. Cycloadduct 4 was converted to the iridoid glycoside (+)-geniposide in 10 steps.

The iridoids are a large family of monoterpene natural products structurally characterized by a highly oxygenated *cis*-fused cyclopenta[*c*]pyran ring system.¹ Members of this class embody a diverse range of biological activities,^{1d, 2} which has made them popular synthetic targets.³ Despite enormous progress, synthetic approaches to iridoid natural products that incorporate their natural β -glycosides remain rare due to difficulties associated with the glycosidation.⁴

In the course of our studies in the area of phosphine organocatalysis,^{5, 6, 7, 8, 9} we explored intramolecular variants of Lu's phosphine catalyzed [3+2] cycloaddition reported in 1995.^{5a, 10, 11, 12} Whereas the intermolecular cycloaddition generally provides mixtures of regio- and stereoisomeric adducts, the intramolecular cycloaddition delivers diquinanes in structurally homogenous form. As a regio- and stereocontrolled intermolecular cycloaddition of this type would be of great utility, we explored dipolarophiles possessing γ -heteroatom substitution, as in the case of enones **3**, which are prepared conveniently through the Achmatowicz reaction of furfuryl alcohol.¹³ It was postulated that such γ -heteroatom substitution should (a) activate the dipolarophile toward cycloaddition, (b) reinforce the inherent regiochemical bias, and (c) direct the diastereofacial selectivity of cycloaddition.

Here, we report that "Achmatowicz enones" **3** engage in regio- and stereocontrolled intermolecular [3+2] cycloaddition, thus providing direct access to the iridoid ring system **4**. This methodology was applied to the synthesis of the iridoid glycoside (+)-geniposide **1**,¹⁴ which displays antitumor¹⁵ and anti-inflammatory¹⁶ activity. The total asymmetric synthesis of (+)-geniposide **1** constitutes a formal synthesis of its aglycone (+)-genipin **2**,^{17, 18} which recently has garnered attention as an effective treatment for type II diabetes (Scheme 1).¹⁹

*mkrische@mail.utexas.edu.

Supporting Information Available. Spectral data for all new compounds (¹H NMR, ¹³C NMR, IR, HRMS). Single crystal X-ray diffraction data for the 4,5-dichlorophthalimide adduct of (*S*)-3a and the cycloadduct **4**. This material is available free of charge *via* the internet at <http://pubs.acs.org>.

Exposure of commercially available furfuryl alcohol to *m*-CPBA in dichloromethane delivered lactol *rac*-**3a** in 78% yield,¹² which was converted to the pivalate *rac*-**3b** in 80% yield. Kinetic resolution of *rac*-**3b** was attempted under the conditions of palladium catalyzed allylic substitution employing *p*-nitrobenzyl alcohol as nucleophile.²⁰ After careful optimization, it was found that chirally modified palladium catalysts arising from the combination of $[(\eta^3\text{-C}_3\text{H}_5)\text{PdCl}]_2$ (1.0 mol %) and the parent Trost ligand (3 mol %) enable recovery of the allylic pivalate (*S*)-**3b** in 92% ee in a satisfactory 70% theoretical isolated yield. Optically pure (*S*)-**3b** is readily achieved upon recrystallization from pentane. The byproduct (*R*)-**3c** was isolated in 96% theoretical isolated yield in 68% ee. Absolute stereochemistry was determined by single crystal X-ray diffraction analysis of 4,5-dichlorophthalimide adduct of (*S*)-**3b** using the anomalous dispersion method, and is consistent with the stereochemical models developed by Trost for related kinetic resolutions (Scheme 2).²¹

With (*S*)-**3b** in hand, the phosphine-catalyzed [3+2] cycloaddition was attempted using ethyl-2,3-butadienoate. Gratifyingly, using triphenylphosphine as catalyst (10 mol %) in toluene (0.2 M) at 110 °C, the desired cycloadduct **4** was obtained in 63% isolated yield after 30 minutes as a single regio- and stereoisomer, as confirmed by single crystal X-ray diffraction analysis. Note that while two equivalents of (*S*)-**3b** are used in the cycloaddition, unreacted (*S*)-**3b** was recovered in 96% isolated yield.

Installation of the α,β -unsaturated methyl ester was accomplished in a stepwise fashion. Cycloadduct **4** was converted to the cyanohydrin, which upon elimination furnished the α,β -unsaturated nitrile **5** in 60% isolated yield over two steps. Chemoselective reduction of the α,β -unsaturated ethyl ester of compound **5** using DIBAL-H delivered the allylic alcohol **6** in 62% yield. Further conversion of nitrile **6** to the methyl ester was made difficult due to the sensitivity of the enol moiety to acid, as well as the base sensitivity of the pivalate. Using the Ghaffar-Parkins catalyst,²² hydration of nitrile **6** to the primary amide **7** was accomplished in 87% isolated yield. Nitrosation of amide **7** resulted in hydrolysis to furnish the carboxylic acid.²³ During the course of this reaction the primary alcohol was converted to the acetate. Exposure of carboxylic acid to TMS-diazomethane delivered the methyl ester **8** in 74% yield over two steps.

To complete the synthesis of (+)-geniposide **1**, installation of the β -glucoside was required. Quite serendipitously, it was found that upon exposure of methanolic solutions of compound **8** to Otera's catalyst,²⁴ acetate removal was accompanied by transfer of the pivaloyl moiety to provide lactol **9** in 73% yield as a 5:1 mixture of epimers at the anomeric carbon. Compound **9** was independently prepared from commercially available (+)-genipin **2**, thus corroborating its structural assignment and providing a convenient source of forefront material. Glycosidation of lactol **9** employing the trichloroacetimidate as the glycosyl donor delivered the β -glucoside **10** in 62% yield as a single diastereomer. Global deprotection of **10** using aqueous lithium hydroxide in acetonitrile²⁵ provided (+)-geniposide **1** in 61% isolated yield, the spectral data of which corresponded to that of previously reported material.²⁶

In summary, we report an asymmetric synthesis of the iridoid glucoside (+)-geniposide **1** in 14 steps. A key feature of our synthetic strategy involves rapid construction of the *cis*-fused cyclopenta[c]pyran iridoid ring system employing a phosphine catalyzed intermolecular [3+2] cycloaddition. Unlike typical intermolecular cycloadditions employing acrylates, fumarates and maleates, which provide adducts as mixtures of regio- and diastereoisomers, the unique structural features of γ -heteroatom substituted enones **3** combine high levels of reactivity with excellent regio- and stereocontrol.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


Acknowledgments

Acknowledgment is made to the Robert A. Welch Foundation and NSF (CHE-0749016).

References

- (1). For reviews that catalog members of the iridoid family, see: (a) El-Naggar LJ, Beal JL. *J. Nat. Prod* 1980;43:649. (b) Boros CA, Stermitz FR. *J. Nat. Prod* 1990;53:1055. (c) Dinda B, Debnath S, Harigaya Y. *Chem. Pharm. Bull* 2007;55:159. [PubMed: 17268091] (d) Dinda B, Debnath S, Harigaya Y. *Chem. Pharm. Bull* 2007;55:689. [PubMed: 17473457]
- (2). For reviews of the biological activity of iridoid natural products, see: (a) Villaseñor IM. *Anti-Infl. Anti-Allergy Agent Med. Chem* 2007;6:307. (b) Tundis R, Loizzo MR, Menichini F, Statti GA, Menichini F. *Mini-Rev. Med. Chem* 2008;8:399. [PubMed: 18473930]
- (3). For reviews on the synthesis of iridoid natural products, see: (a) Tietze L-F. *Angew. Chem. Int. Ed. Engl* 1983;22:829. (b) Bianco A. *Stud. Nat. Prod. Chem* 1990;7:439. (c) Bianco A. *Pure Appl. Chem* 1994;66:2335. (d) Isoe S. *Stud. Nat. Prod. Chem* 1995;16:289. (e) Nangia A, Prasuna G, Rao PB. *Tetrahedron* 1997;53:14507. (f) Franzyk H. *Prog. Chem. Org. Nat. Prod* 2000;79:1.
- (4). For syntheses of iridoid glycosides see: (a) Büchi G, Carlson JA, Powell JE, Tietze L-F. *J. Am. Chem. Soc* 1970;92:2165. (b) Partridge JJ, Chadha NK, Uskoković MR. *J. Am. Chem. Soc* 1973;95:532. (c) Büchi G, Carlson JA, Powell JE, Tietze L-F. *J. Am. Chem. Soc* 1973;95:540. (d) Tietze L-F. *Angew. Chem. Int. Ed. Engl* 1973;12:757. (e) Tietze L-F. *Chem. Ber* 1974;107:2499. (f) Tietze L-F, Fischer R, Remberg G. *Liebigs Ann. Chem* 1987:971. (g) Piccini P, Vidari G, Zanoni G. *J. Am. Chem. Soc* 2004;126:5088. [PubMed: 15099090] (h) Mangion IK, Macmillan DWC. *J. Am. Chem. Soc* 2005;127:3696. [PubMed: 15771494]
- (5). For reviews on phosphine organocatalysis, see: (a) Lu X, Zhang C, Xu Z. *Acc. Chem. Res* 2001;34:535. [PubMed: 11456471] (b) Methot JL, Roush WR. *Adv. Synth. Catal* 2004;346:1035. (c) Lu X, Du Y, Lu C. *Pure Appl. Chem* 2005;77:1985. Ye L-W, Zhou J, Tang Y. *Chem. Soc. Rev* 2008;37:1140. [PubMed: 18497927] (d) Kwong CK-W, Fu MY, Lam CS-L, Toy PH. *Synthesis* 2008:2307.
- (6). For phosphine catalyzed cycloisomerization of electron deficient bisolefins, see: (a) Wang L-C, Luiz A-L, Agapiou K, Jang H-Y, Krische MJ. *J. Am. Chem. Soc* 2002;124:2402. [PubMed: 11890765] (b) Agapiou K, Krische MJ. *Org. Lett* 2003;5:1737. [PubMed: 12735765] (c) Luis A-L, Krische MJ. *Synthesis* 2004:2579. (d) Frank SA, Mergott DJ, Roush WR. *J. Am. Chem. Soc* 2002;124:2404. [PubMed: 11890766]
- (7). For phosphine catalyzed regioretentive allylic substitutions of Morita-Baylis-Hillman acetates, see: (a) Cho C-W, Kong JR, Krische MJ. *Org. Lett* 2004;6:1337. [PubMed: 15070331] (b) Cho C-W, Krische MJ. *Angew. Chem. Int. Ed* 2004;43:6689. (c) Park H, Cho C-W, Krische MJ. *J. Org. Chem* 2006;71:7892. [PubMed: 16995707] (d) For an asymmetric variant, see:
- (8). For phosphine catalyzed α -arylation of enones employing hypervalent bismuth reagents, see: Koech PK, Krische MJ. *J. Am. Chem. Soc* 2004;126:5350. [PubMed: 15113193] (b) Koech PK, Krische MJ. *Tetrahedron* 2006;62:10594.
- (9). For merged Tsuji-Trost-Morita-Baylis-Hillman cyclizations of enoneallyl acetates, see: (a) Jellerichs BG, Kong JR, Krische MJ. *J. Am. Chem. Soc* 2003;125:7758. [PubMed: 12822967] (b) Webber P, Krische MJ. *J. Org. Chem* 2008;73:9379.
- (10). For phosphine catalyzed intramolecular [3+2] cycloaddition of acetylenic esters to enones, see: Wang JC, Ng SS, Krische MJ. *J. Am. Chem. Soc* 2003;125:3682. [PubMed: 12656582] (b) Wang J-C, Krische MJ. *Angew. Chem. Int. Ed* 2003;42:5855.
- (11). For the seminal phosphine catalyzed [3+2] cycloaddition reported by Lu, see: Zhang C, Lu X. *J. Org. Chem* 1995;60:2906. (b) Xu Z, Lu X. *Tetrahedron Lett* 1997;38:3461. (c) Xu Z, Lu X. *Tetrahedron Lett* 1999;40:549. (d) Xu Z, Lu X. *J. Org. Chem* 1998;63:5031. (e) Du Y, Lu X, Yu Y. *J. Org. Chem* 2002;67:8901. [PubMed: 12467406]

- (12). For related phosphine catalyzed cycloadditions, see: (a) Xu Z, Lu X. *Tetrahedron Lett* 1997;38:3461. (b) Xu Z, Lu X. *J. Org. Chem* 1998;63:5031. Zhu X-F, Lan J, Kwon O. *J. Am. Chem. Soc* 2003;125:4716. [PubMed: 12696883] (b) Zhu X-F, Schaffner A-P, Li RC, Kwon O. *Org. Lett* 2005;7:2977. [PubMed: 15987184] (c) Tran YS, Kwon O. *J. Am. Chem. Soc* 2007;129:12632. [PubMed: 17914823] (d) Henry CE, Kwon O. *Org. Lett* 2007;9:3069. [PubMed: 17629288] (e) Creech GS, Kwon O. *Org. Lett* 2008;10:429. [PubMed: 18173275]
- (13) (a). Achmatowicz O Jr, Bukowski P, Szechner B, Zwierzchowska Z, Zamojski A. *Tetrahedron* 1971;27:1973. (b) Lefebvre Y. *Tetrahedron Lett* 1972;2:133.
- (14). For the isolation of (+)-geniposide, see: Inouye H, Saito S. *Tetrahedron Lett* 1969;28:2347.
- (15) (a). Ueda S, Iwahashi Y, Tokuda H. *J. Nat. Prod* 1991;54:1677. [PubMed: 1667413] (b) Lee M-J, Hsu J-D, Wang C-J. *Anticancer Res* 1995;15:411. [PubMed: 7763014]
- (16). Koo H-J, Lim K-H, Jung H-J, Park E-H. *J. Ethnopharmacol* 2006;103:496. [PubMed: 16169698]
- (17). For the isolation of (+)-genipin, see: Djerassi C, Gray JD, Kincl FA. *J. Org. Chem* 1960;25:2174.
- (18). For the conversion of (+)-geniposide to its aglycone (+)-genipin, see: (a) Endo T, Taguchi H. *Chem. Pharm. Bull* 1973;21:2684. (b) Tanaka M, Kigawa M, Mitsuhashi H, Wakamatsu T. *Heterocycles* 1991;32:1451. (c)
- (19). Zhang C-Y, Parton LE, Ye CP, Krauss S, Shen R, Lin C-T, Porco JA, Lowell BB. *Cell Metab* 2006;3:417. [PubMed: 16753577]
- (20). For related allylic alkylations, see: (a) van der Deen H, van Oeveren A, Kellogg RM, Feringa BL. *Tetrahedron Lett* 1999;40:1755. (b) Comely AC, Eelkema R, Minnaard AJ, Feringa BL. *J. Am. Chem. Soc* 2003;125:8714. [PubMed: 12862452] (c) Babu RS, O'Doherty GA. *J. Am. Chem. Soc* 2003;125:12406. [PubMed: 14531673] (d) Babu RS, Zhou M, O'Doherty GA. *J. Am. Chem. Soc* 2004;126:3428. [PubMed: 15025462] (e) Trost BM, Toste FD. *J. Am. Chem. Soc* 2003;125:3090. [PubMed: 12617676]
- (21). Trost BM, Machacek MR, Aponick A. *Acc. Chem. Res* 2006;39:747. [PubMed: 17042475]
- (22) (a). Parkins AW, Ghaffar T. *Tetrahedron Lett* 1995;47:8657. (b) Ghaffar T, Parkins A. *J. Mol. Catal. A* 2000;160:249.
- (23). Lin R, Castells J, Rapoport H. *J. Org. Chem* 1998;63:4069.
- (24). Otera J, Dan-oh N, Hitosi N. *J. Org. Chem* 1991;56:5307.
- (25). Mouriès C, Deguin B, Koch M, Tillequin F. *Helv. Chim. Acta* 2003;86:147.
- (26) (a). Güvenalp Z, Kiliç N, Kazaz C, Kaya Y, Demirezer Ö. *Turk. J. Chem* 2006;30:515. (b) Morota T, Sasaki H, Nishimura H, Sugama K, Chin M, Mitsuhashi H. *Phytochemistry* 1989;28:2149.



Scheme 1.
Retrosynthetic analysis of (+)-geniposide **1** and (+)-genipin **2**.



**Scheme 2.**Kinetic resolution of *rac*-**3b** using palladium catalyzed allylic substitution.

Table 1

Conversion of (S)-3b to (+)-geniposide 1 via phosphine catalyzed [3+2] cycloaddition.^a^aSee supporting information for detailed experimental procedures.